Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma

BACKGROUND AND AIM: The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Yoshihiko, Yamamoto, Atsushi, Mimura, Takuya, Kushida, Saeko, Hirohata, Seiya, Yoon, Seitetsu, Hirano, Hirotaka, Kim, Soo Ki, Hatazawa, Yuri, Momose, Kenji, Hayashi, Hiroki, Kado, Takuo, Nishi, Katsuhisa, Tanaka, Hidenori, Matsuura, Takanori, Yoshida, Ryutaro, Asaji, Naoki, Yasutomi, Eiichiro, Shiomi, Yuuki, Minami, Akihiro, Komatsu, Shohei, Fukumoto, Takumi, Ueda, Yoshihide, Kodama, Yuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366485/
https://www.ncbi.nlm.nih.gov/pubmed/37496817
http://dx.doi.org/10.1002/jgh3.12932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366485/
https://www.ncbi.nlm.nih.gov/pubmed/37496817
http://dx.doi.org/10.1002/jgh3.12932

Ejemplares similares